Key result
Endothelin-1 receptor antagonists bosentan and macitentan partially reversed cyclosporine-induced changes in renal function and hemodynamics in normotensive and hypertensive rats.
Why the study?
Do endothelin-1 receptor antagonists (bosentan or macitentan) improve cyclosporine-A-induced nephrotoxicity and renal hemodynamic changes in normotensive and hypertensive rats?
Do endothelin-1 receptor antagonists (bosentan or macitentan) improve cyclosporine-A-induced nephrotoxicity and renal hemodynamic changes in normotensive and hypertensive rats?
Endothelin-1 receptor antagonists bosentan and macitentan partially reverse cyclosporine-A-induced nephrotoxicity and renal hemodynamic changes in normotensive and hypertensive rats.
No takes yet. Share an insight, caveat, or question.
No immediate clinical implications for cyclosporine nephrotoxicity; extends preclinical evidence for endothelin antagonists.
Caires et al. (2017) studied Cyclosporine-A induced nephrotoxicity. Bosentan and macitentan vs. Control group and CsA alone group was evaluated on Renal function (plasma creatinine and urea, MAP, RBF, and RVR). Endothelin-1 receptor antagonists bosentan and macitentan partially reversed cyclosporine-induced changes in renal function and hemodynamics in normotensive and hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: